Overview

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-31

Target enrollment:

Participant gender:

Summary

This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Normunity AccelCo, Inc.